Illumina news
The WiseView Research desk's stories that name Illumina, the latest headlines about it, and the trades members of Congress and company insiders have disclosed. The ILMN page →
- HeadlineIllumina (ILMN) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
- HeadlineIllumina To Webcast Upcoming Investor Conference
- HeadlineIllumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth
- HeadlineIllumina: NovaSeq X And Consumables Sustain Momentum
- HeadlineILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
- HeadlineIllumina BioInsight Platform expands with new software to accelerate the path from sequencing to discovery
- HeadlineWill Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
- HeadlineIllumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughs
- HeadlineIllumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026
- HeadlineIllumina releases SpliceAI2 to help advance rare disease research
- CongressGilbert Cisneros bought $1,001 - $15,000 of ILMN
- CongressLisa McClain bought $1,001 - $15,000 of ILMN
- CongressThomas H. Kean bought $1,001 - $15,000 of ILMN
Headlines link to their publishers. Members of Congress disclose ranges, not exact amounts, and may file weeks after the trade; insider filings are open-market purchases and sales from SEC Form 4. For information only, not investment advice.